Pancreatic Cancer Research

ResearcherChristian-Albrechts-Universität zu KielActive in the last 2 years

H. Schäfer

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-6936-9090; OpenAlex author ID A5080546850. Sources: OpenAlex.

Their work

Papers
25 (first author 4, last author 6)
Trials
0
Grants
0
Labs led
1
Collaborators
40
Papers, trials and grants by year

2012: 2 papers · 2013: 2 papers · 2014: 3 papers · 2015: 1 paper · 2016: 1 paper · 2017: 2 papers · 2018: 2 papers · 2019: 2 papers · 2020: 1 paper · 2021: 3 papers · 2022: none · 2023: 4 papers · 2024: 1 paper · 2025: 1 paper

Papers 25

  1. Transmembrane Protease Serine 11B Modulates Lactate Transport Through SLC16A1 in Pancreatic Ductal Adenocarcinoma-A Functional Link to Phenotype Heterogeneity. Last author DOI 10.3390/ijms26115398↗
  2. The Role of Nrf2 in the Regulation of Mitochondrial Function and Ferroptosis in Pancreatic Cancer. First author DOI 10.3390/antiox13060696↗
  3. NF-κB/RelA controlled A20 limits TRAIL-induced apoptosis in pancreatic cancer. Co-author DOI 10.1038/s41419-022-05535-9↗
  4. Expression and role of the immune checkpoint regulator PD-L1 in the tumor-stroma interplay of pancreatic ductal adenocarcinoma. Co-author DOI 10.3389/fimmu.2023.1157397↗
  5. Hepatic myofibroblasts exert immunosuppressive effects independent of the immune checkpoint regulator PD-L1 in liver metastasis of pancreatic ductal adenocarci… Co-author DOI 10.3389/fonc.2023.1160824↗
  6. Monocarboxylate Transporter-1 (MCT1)-Mediated Lactate Uptake Protects Pancreatic Adenocarcinoma Cells from Oxidative Stress during Glutamine Scarcity Thereby P… Last author DOI 10.3390/antiox12101818↗
  7. Insulin Receptor in Pancreatic Cancer-Crown Witness in Cross Examination. Co-author DOI 10.3390/cancers13194988↗
  8. Initiation of Pancreatic Cancer: The Interplay of Hyperglycemia and Macrophages Promotes the Acquisition of Malignancy-Associated Properties in Pancreatic Duct… Co-author DOI 10.3390/ijms22105086↗
  9. Programmed Death-Ligand 1 (PD-L1) Expression Is Induced by Insulin in Pancreatic Ductal Adenocarcinoma Cells Pointing to Its Role in Immune Checkpoint Control. Last author DOI 10.3390/medsci9030048↗
  10. Impact of the Monocarboxylate Transporter-1 (MCT1)-Mediated Cellular Import of Lactate on Stemness Properties of Human Pancreatic Adenocarcinoma Cells †. Last author DOI 10.3390/cancers12030581↗
  11. Metastasis of pancreatic cancer: An uninflamed liver micromilieu controls cell growth and cancer stem cell properties by oxidative phosphorylation in pancreati… Co-author DOI 10.1016/j.canlet.2019.03.039↗
  12. NF-κB Dependent Chemokine Signaling in Pancreatic Cancer. First author DOI 10.3390/cancers11101445↗
  13. Diabetes as risk factor for pancreatic cancer: Hyperglycemia promotes epithelial-mesenchymal-transition and stem cell properties in pancreatic ductal epithelia… Co-author DOI 10.1016/j.canlet.2017.12.004↗
  14. TRAIL/NF-κB/CX3CL1 Mediated Onco-Immuno Crosstalk Leading to TRAIL Resistance of Pancreatic Cancer Cell Lines. Co-author DOI 10.3390/ijms19061661↗
  15. Role of CCL20 mediated immune cell recruitment in NF-κB mediated TRAIL resistance of pancreatic cancer. Co-author DOI 10.1016/j.bbamcr.2017.02.005↗
  16. The hepatic microenvironment essentially determines tumor cell dormancy and metastatic outgrowth of pancreatic ductal adenocarcinoma. Co-author DOI 10.1080/2162402x.2017.1368603↗
  17. Investigational histone deacetylase inhibitors for treating pancreatic adenocarcinoma. First author DOI 10.1080/13543784.2016.1240167↗
  18. CD4+ T cells potently induce epithelial-mesenchymal-transition in premalignant and malignant pancreatic ductal epithelial cells-novel implications of CD4+ T ce… Co-author DOI 10.1080/2162402x.2014.1000083↗
  19. L1CAM promotes enrichment of immunosuppressive T cells in human pancreatic cancer correlating with malignant progression. Co-author DOI 10.1016/j.molonc.2014.03.001↗
  20. c-Rel is a critical mediator of NF-κB-dependent TRAIL resistance of pancreatic cancer cells. Co-author DOI 10.1038/cddis.2014.417↗
  21. Comparative characterization of stroma cells and ductal epithelium in chronic pancreatitis and pancreatic ductal adenocarcinoma. Co-author DOI 10.1371/journal.pone.0094357↗
  22. Targeting apoptosis pathways in pancreatic cancer. Last author DOI 10.1016/j.canlet.2010.10.015↗
  23. Inhibition of the Nrf2 transcription factor by the alkaloid trigonelline renders pancreatic cancer cells more susceptible to apoptosis through decreased protea… Last author DOI 10.1038/onc.2012.493↗
  24. Characterisation of FAP-1 expression and CD95 mediated apoptosis in the A818-6 pancreatic adenocarcinoma differentiation system. Co-author DOI 10.1016/j.diff.2011.11.013↗
  25. The 'N-factors' in pancreatic cancer: functional relevance of NF-κB, NFAT and Nrf2 in pancreatic cancer. First author DOI 10.1038/oncsis.2012.35↗

Closest collaborators

The 25 strongest of 40 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Susanne Sebens · 16 shared papers, 2013–2025 · strength 1.70
  2. Christoph Röcken · 11 shared papers, 2014–2025 · strength 1.32
  3. Claudia Geismann · 8 shared papers, 2013–2025 · strength 0.96
  4. Alexander Arlt · 11 shared papers, 2012–2023 · strength 0.89
  5. Dinara M. Baiskhanova · 2 shared papers, 2024–2025 · strength 0.72
  6. Sascha Rahn · 5 shared papers, 2018–2023 · strength 0.61
  7. Steffen Markus Heckl · 4 shared papers, 2021–2023 · strength 0.60
  8. Tina Daunke · 4 shared papers, 2021–2023 · strength 0.60
  9. Daniela Wesch · 6 shared papers, 2014–2023 · strength 0.58
  10. Günter Schneider · 6 shared papers, 2014–2023 · strength 0.51
  11. Anna Trauzold · 3 shared papers, 2014–2025 · strength 0.50
  12. Silje Beckinger · 3 shared papers, 2021–2023 · strength 0.47
  13. Jan-Paul Gundlach · 3 shared papers, 2017–2023 · strength 0.33
  14. Nourhane Ammar · 2 shared papers, 2020–2023 · strength 0.32
  15. Lennart Lenk · 4 shared papers, 2015–2019 · strength 0.25
  16. Christian Röder · 2 shared papers, 2014–2023 · strength 0.23
  17. Ole Helm · 4 shared papers, 2014–2018 · strength 0.21
  18. Dieter Saur · 3 shared papers, 2017–2019 · strength 0.20
  19. Bence Sipos · 4 shared papers, 2014–2017 · strength 0.17
  20. Christian Schneeweis · 1 shared paper, 2023 · strength 0.17
  21. Anna Maxi Wandmacher · 1 shared paper, 2023 · strength 0.16
  22. Christian P. Pilarsky · 1 shared paper, 2023 · strength 0.16
  23. Hendrik Ungefroren · 3 shared papers, 2012–2018 · strength 0.15
  24. Hendrike Knaack · 2 shared papers, 2018–2019 · strength 0.15
  25. Lilli Otto · 1 shared paper, 2021 · strength 0.13

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.